Sun Mingfei, Yang Zhan, Ma Ziwei, Wu Jinbo, Lu Shaoying
Department of Vascular Surgery, The First Affiliated Hospital of Xi'an JiaoTong University, Xi'an, Shaanxi, China.
Department of Vascular Surgery, The First Affiliated Hospital of Henan University, Kaifeng, Henan, China.
Front Bioeng Biotechnol. 2025 May 15;13:1570668. doi: 10.3389/fbioe.2025.1570668. eCollection 2025.
Home discovery of myocardial infarction can significantly improve the rate of treatment. Cardiac troponin I (cTnI), as a biochemical marker that has been introduced into clinical diagnosis and treatment guidelines, can effectively predict the occurrence of myocardial infarction. We constructed highly stable nanozyme based on FeO nanoparticles and prepared rapid detection reagents for myocardial infarction by modifying anti-cTnI antibodies. The results showed that the nanozyme with an average particle size of 200 nm had peroxidase activity and could effectively catalyze 3,3', 5,5'-tetramethylbenzidine (TMB). With a sensitivity of up to 1.5 ng/mL, the kit showed superior performance than commercial colloidal gold assay kits, and could effectively detect cTnI in serum with an overall compliance rate of 92.1%. The study provides a new approach to home detection of heart attacks.
在家中发现心肌梗死可显著提高治疗率。心肌肌钙蛋白I（cTnI）作为一种已被纳入临床诊断和治疗指南的生化标志物，能够有效预测心肌梗死的发生。我们基于FeO纳米颗粒构建了高度稳定的纳米酶，并通过修饰抗cTnI抗体制备了心肌梗死快速检测试剂。结果表明，平均粒径为200 nm的纳米酶具有过氧化物酶活性，能够有效催化3,3',5,5'-四甲基联苯胺（TMB）。该试剂盒灵敏度高达1.5 ng/mL，表现优于市售胶体金检测试剂盒，能够有效检测血清中的cTnI，总体符合率为92.1%。该研究为在家中检测心脏病发作提供了一种新方法。
